• Recruiting

NCT04108624: Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients

Updated: May 26

Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients

MRD2stop - university of chicago

Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients


This study is to assess for Measurable Residual Disease (MRD) in multiple myeloma at a deeper level than what is currently available by combining novel imaging and laboratory techniques, determine if patients who are MRD-negative by these multiple modalities can safely and effectively discontinue post-transplant maintenance therapy, and determine if liquid biopsies is a more accurate and/or less invasive sampling technique for multiple myeloma.


The purpose of this research is to determine if patients who are MRD-negative by multiple modalities ("multimodality MRD-negative") can safely and effectively discontinue post-transplant maintenance therapy (single agent lenalidomide, pomalidomide, bortezomib, or ixazomib) after receiving at least one year of maintenance therapy.


Sponsor:

University of Chicago


Location

United States, Illinois

 

ClinicalTrials.gov Identifier: NCT04108624


Official Title: A Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple Myeloma (MRD2STOP)


First Posted: September 30, 2019


Click here for details on ClinicalTrials.gov

 

MRD Testing

Adaptive Biotechnologies

 

Location

United States, Illinois







Posts Archive